A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

NCT02494258 PHASE2 COMPLETED Results posted

Rollover study supporting hematological disorder indications from Celgene sponsored CC-486 (oral azacitidine) protocols eligible for participation in the study.

Details

Lead sponsor	Celgene
Phase	PHASE2
Status	COMPLETED
Enrolment	5
Start date	Thu Oct 22 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Apr 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Hematologic Neoplasm
• Neoplasms
• Hematologic Malignancies

Interventions

• CC-486

Countries

United Kingdom, United States